is an experimental therapeutic vaccine currently in clinical trial. The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to...
- Mechanism
- Curator reviewed
VIR201 uses DNA vaccine technology called Co-X-Gene in which HIV and human genetic material have been grafted on to a harmless fowlpox virus. This fowlpox vector carries genetic material for HIV proteins gag and pol. The aim of this component of the vaccine is to stimulate HIV-specific immune responses in people who have very low levels of HIV in their blood due to antiretroviral therapy. The vaccine also carries genetic material to stimulate the cytokine or immune system messenger called interferon gamma which is associated with delayed disease progression. The aim of this second component of the vaccine is to boost levels of interferon gamma and improve immune functioning.
- Primary indication
- Investigated for use/treatment in HIV infection.Curator reviewed
- Code names
- VIR201
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with VIR201, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account